By Cecilia Butini

 

Roche Holding AG said Tuesday that a phase-3 clinical trial assessing an antibody cocktail to treat Covid-19 in non-hospitalized patients met its primary endpoint.

The Swiss pharma major said its investigational antibody cocktail of casirivimab and imdevimab reduced the risk of hospitalization or death by 70% compared with a placebo.

The drugs also met the secondary endpoints of the study, which included the ability to reduce symptom duration from 14 to 10 days, the company said.

It added that it would soon share results from the trial with regulatory authorities and from another phase 2/3 study on the use of the same drugs in hospitalized patients.

On Feb 26, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion supporting use of the cocktail for the treatment of Covid-19 infections.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

March 23, 2021 02:35 ET (06:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.